BioMarin Pharmaceutical Insiders Sold US$6.7m Of Shares Suggesting Hesitancy
BioMarin Pharmaceutical Insiders Sold US$6.7m Of Shares Suggesting Hesitancy
Over the past year, many BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, if numerous insiders are selling, shareholders should investigate more.
在過去的一年中,許多拜瑪林製藥(BioMarin Pharmaceutical Inc.,納斯達克股票代碼爲BMRN)內部人士出售了公司的大部分股份,這可能引起了投資者的興趣。通常在評估內部人員交易時,了解內部人員是否在買入股票更爲有幫助,因爲內部人員出售股票可能有多種解釋。不過,如果很多內部人員都在出售股票,股東應該加以調查。
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
雖然我們不認爲股東應該簡單地跟隨內部交易,但完全忽略內部交易將是愚蠢的。
The Last 12 Months Of Insider Transactions At BioMarin Pharmaceutical
BioMarin製藥的最近12個月內內部交易情況
In the last twelve months, the biggest single sale by an insider was when the President of Worldwide Research & Development, Henry Fuchs, sold US$3.0m worth of shares at a price of US$85.18 per share. So we know that an insider sold shares at around the present share price of US$82.29. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.
在過去的12個月中,一位內部人員的最大單筆出售是全球研發總裁Henry Fuchs以每股85.18美元的價格出售300萬美元的股票。所以我們知道,一位內部人員在現價82.29美元左右的價格出售了股票。我們通常不喜歡看到內部人員出售股票,但是出售價格越低,就越令我們擔心。考慮到這筆交易是以現行價格進行的,這使我們有點謹慎,但幾乎沒有太大的問題。
In the last year BioMarin Pharmaceutical insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在過去的一年中,BioMarin製藥的內部人員沒有購買任何公司股票。下圖顯示了過去一年內的內部交易情況(包括公司和個人)。如果單擊圖表,您可以看到所有單獨的交易,包括股價、個人和日期!
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240711/0-c7eeba656b52fac78cb24004f6bf227b-0-0e63c2db72fa0c026fa66c1c95736eba.png/big)
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
對於那些喜歡發現潛力股票的人,可以免費查看最新內部交易股票的小盤公司名單,這可能正是您要找的機會。
Does BioMarin Pharmaceutical Boast High Insider Ownership?
BioMarin製藥是否擁有高比例的內部股權?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. BioMarin Pharmaceutical insiders own about US$116m worth of shares (which is 0.7% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
測試公司領導者和其他股東之間的一致性的另一種方法是查看他們擁有多少股份。高比例的內部股權通常使公司領導更加關注股東利益。BioMarin Pharmaceutical的內部人員擁有價值約爲1160萬美元的股票(佔公司總股本的0.7%)。大多數股東會對此類內部股權感到滿意,因爲它表明管理層的激勵與其他股東的激勵一致。
What Might The Insider Transactions At BioMarin Pharmaceutical Tell Us?
BioMarin製藥的內部交易可能告訴我們什麼?
There haven't been any insider transactions in the last three months -- that doesn't mean much. While we feel good about high insider ownership of BioMarin Pharmaceutical, we can't say the same about the selling of shares. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
在過去的三個月中沒有進行任何內部交易,但這並不意味着什麼。雖然我們對BioMarin製藥的高比例內部股權感到滿意,但對出售股票感到擔憂。如果您像我一樣,可能需要考慮這家公司會增長還是會縮小。幸運的是,您可以查看此免費報告,其中顯示了分析師對其未來的預測。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。